OmniAb
NASDAQ: OABIEmeryville, US · Founded 2022 · Delaware corporation
Find your way into OmniAb
705 people in our graph share verified history with the OmniAb team — schools, employers, funds. One of them is your warm intro.
René Kuijtenunlockedknows Amechi Nwachuku · together at McKinsey & Company (overlapped)
×8knows the team · via McKinsey & Company
×2knows the team · via Bayer HealthCare Diabetes Care
knows the team · via Amgen
OmniAb develops transgenic animal platforms engineered to generate human antibodies for therapeutic drug discovery, serving biopharmaceutical researchers and drug developers.
Founders & leadership
KG
Kurt GustafsoninChief Financial OfficerKurt Gustafson held multiple finance roles at Amgen from 1991 to 2006, including Treasurer, VP of Corporate Financial Planning and Analysis, and VP Finance for Manufacturing, before serving as CFO at Halozyme Therapeutics and Spectrum Pharmaceuticals. He holds a BA in Accounting from North Park University and an MBA from UCLA.
CB
Charles BerkmaninChief Legal Officer & Secretary
MF
Matt FoehrinChief Executive Officer
AN
Amechi NwachukuinChief Operating OfficerChief Operating Officer at OmniAb. Nwachuku has held leadership roles across biotech, medtech, pharmaceuticals, and consumer health, with experience in P&L management and strategy development across international teams.
KA
Kurt A. GustafsoninExecutive Vice President, Finance and Chief Financial OfficerKurt Gustafson holds a BA in Accounting from North Park University and an MBA from UCLA. He spent over a decade in finance roles at Amgen, including Treasurer and VP of Corporate Financial Planning and Analysis, before serving as CFO of Amgen's International Operations and later as CFO at Halozyme Therapeutics and Spectrum Pharmaceuticals, where he led financing rounds and strategic acquisitions. He joined OmniAb as CFO in March 2022.
CS
Charles S. BerkmaninChief Legal Officer & Secretary
Board
JH
John HigginsBoard director
CR
Carolyn R. BertozziBoard director
JC
Jennifer CochranBoard director
PJ
Philip J. GotwalsBoard director
SL
Steve LoveBoard director
SC
Steve CrouseBoard director
Reported raises · per SEC filings
Form D private placements$30M disclosed across 1 round · 2025
▶$30MraisedSep 2025 · 15 investors · BiotechnologyRule 506(b)
▶$30MraisedSep 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carolyn R. BertozziDirector
- Kurt GustafsonExecutive Officer
- John HigginsDirector
- Jennifer CochranDirector
- Matthew W. FoehrExecutive Officer, Director
- Charles BerkmanExecutive Officer
- Philip J. GotwalsDirector
- Steve LoveDirector
- Steve CrouseDirector
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- Leerink Partners LLC
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapAbcam33 shared keywordsSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
IQVIA30 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies competing with OmniAb for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
OmniAb Raises 2026 Cash Guidance to $53M | OABI Stock Newsstocktitan.net · Aug 2026
OmniAb Raises 2026 Financial Guidancefinance.yahoo.com · Aug 2026
OmniAb (OABI) Stock Surges After Big Q2 Earnings Beat - StocksToTradestockstotrade.com · Aug 2026
OmniAb (OABI) Q2 2026 Earnings Call Transcript | The Motley Foolfool.com · Aug 2026
OmniAb posts $13.4M Q2 revenue, lifts 2026 outlook | OABI 8-K Filingstocktitan.net · Aug 2026Frequently asked questions
- What does OmniAb do?
- OmniAb develops transgenic animal platforms engineered to generate human antibodies for therapeutic drug discovery, serving biopharmaceutical researchers and drug developers.
- How much funding has OmniAb raised?
- OmniAb has disclosed $30M raised across 1 round.
- Where is OmniAb headquartered?
- OmniAb is headquartered in Emeryville, US.